Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.

Breast cancer (Tokyo, Japan)·2026
Same author

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Breast cancer (Tokyo, Japan)·2026
Same author

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Breast cancer (Tokyo, Japan)·2025
Same author

Utility of Echo-planar Imaging with Compressed Sensitivity Encoding (EPICS) in the Evaluation of Small Breast Cancers Using Diffusion-weighted Imaging with Background Suppression (DWIBS).

Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine·2024
Same author

Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).

Breast cancer research and treatment·2024
Same author

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.

Breast cancer (Tokyo, Japan)·2024

Related Experiment Video

Updated: May 31, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

[Tykerb for breast cancer].

Yasuhiro Suzuki1, Yuki Saito, Takuho Okamura

  • 1Dept. of Breast and Endocrine Surgery, Tokai University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 17, 2011
PubMed
Summary

The epidermal growth factor receptor (EGFR) family, including HER2, is crucial in breast cancer. Trastuzumab resistance necessitates alternative strategies like lapatinib for HER2-positive breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The ErbB receptor family, comprising EGFR, HER2, HER3, and HER4, plays a key role in cellular signaling.
  • HER2-positive breast cancer, accounting for 15-20% of cases, is associated with a poor prognosis.
  • Trastuzumab, an anti-HER2 antibody, shows limited response rates and resistance is a significant clinical challenge.

Purpose of the Study:

  • To review the fundamental aspects of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER) family.
  • To discuss treatment strategies for HER2-positive breast cancer, particularly in the context of trastuzumab resistance.
  • To explore the role and efficacy of lapatinib as an alternative or combination therapy.

Main Methods:

  • Review of existing literature on EGFR/HER family signaling pathways.

More Related Videos

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
10:51

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Published on: April 23, 2021

Related Experiment Videos

Last Updated: May 31, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
10:51

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Published on: April 23, 2021

  • Analysis of clinical data regarding trastuzumab efficacy and resistance mechanisms.
  • Examination of lapatinib's mechanism of action as a tyrosine kinase inhibitor and its clinical application.

    • Main Results:

    • HER2 is a preferred dimerization partner in the HER family, driving cancer progression.
    • Trastuzumab resistance limits its effectiveness, highlighting the need for alternative therapies.
    • Lapatinib, a dual EGFR/HER2 inhibitor, demonstrates activity, especially in combination with capecitabine, for pre-treated patients.

    Conclusions:

    • Understanding HER receptor dimerization and signaling is critical for targeted cancer therapy.
    • Lapatinib represents a viable therapeutic option for HER2-positive breast cancer, particularly in cases of trastuzumab resistance.
    • Combination therapies involving lapatinib may improve outcomes for patients with advanced HER2-positive breast cancer.